Improved Rod Sensitivity as Assessed by Two-Color Dark-Adapted Perimetry in Patients With RPE65-Related Retinopathy Treated With Voretigene Neparvovec-rzyl.
Journal
Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919
Informations de publication
Date de publication:
03 04 2023
03 04 2023
Historique:
medline:
18
4
2023
entrez:
14
4
2023
pubmed:
15
4
2023
Statut:
ppublish
Résumé
The purpose of this study was to evaluate rod-mediated function with two-color dark-adapted perimetry (2cDAP) in patients with RPE65-related retinopathy treated with voretigene neparvovec-rzyl. Following dilation and dark adaptation, 2cDAP and FST were performed. The 2cDAP was measured on an Octopus 900 perimeter (Haag-Streit) with cyan (500 nm wavelength) and red (650 nm wavelength) stimuli. Hill of vision (HOV) analysis was performed on 2cDAP perimetry with Visual Field Modeling and Analysis (VFMA). Full field threshold stimulus testing (FST) was also measured as a secondary measure of rod-mediated function, and assessed on a Diagnosys Espion with the ColorDome stimulator (Diagnosys LLC). Eight eyes from 4 patients who were treated with voretigene bilaterally had rod function assessed by 2cDAP testing at least 1 year after treatment. There was statistically significant improvement in 2cDAP following gene augmentation therapy. HOV VFMA analysis showed widespread improvements that extended beyond the treatment bleb and statistically significant improvement in HOV analysis volumetric measurements post-treatment to cyan and red stimuli. FST testing performed in six eyes from three patients demonstrated statistically significant improvement to all chromatic stimuli following treatment. These findings demonstrated statistically significant improvement in 2cDAP and FST following treatment with voretigene. These findings provide a sensitive method of assessing rod-mediated function in a topographic manner that may be useful in future clinical trials for inherited retinal dystrophies.
Identifiants
pubmed: 37058101
pii: 2785536
doi: 10.1167/tvst.12.4.17
pmc: PMC10117223
doi:
Substances chimiques
retinoid isomerohydrolase
EC 3.1.1.64
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17Subventions
Organisme : NEI NIH HHS
ID : K08 EY026650
Pays : United States
Organisme : NEI NIH HHS
ID : P30 EY010572
Pays : United States
Références
Ophthalmology. 1986 Dec;93(12):1604-11
pubmed: 3808619
Expert Opin Orphan Drugs. 2015 May 4;3(5):563-575
pubmed: 26246977
Ophthalmology. 2018 Nov;125(11):1765-1775
pubmed: 29884405
Orphanet J Rare Dis. 2020 Feb 14;15(1):49
pubmed: 32059734
Lancet. 2014 Oct 25;384(9953):1513-20
pubmed: 25030840
Transl Vis Sci Technol. 2017 Aug 09;6(4):15
pubmed: 28798898
Invest Ophthalmol Vis Sci. 2019 Mar 1;60(4):1122-1131
pubmed: 30901388
Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6177-82
pubmed: 15837919
Invest Ophthalmol Vis Sci. 1979 Apr;18(4):426-9
pubmed: 311766
Invest Ophthalmol Vis Sci. 2000 Jun;41(7):1898-908
pubmed: 10845615
Br J Ophthalmol. 1983 Jul;67(7):405-18
pubmed: 6860608
Arch Ophthalmol. 1971 Dec;86(6):612-22
pubmed: 5316012
Ophthalmology. 2019 Sep;126(9):1273-1285
pubmed: 31443789
Invest Ophthalmol Vis Sci. 2016 Jun 1;57(7):3118-28
pubmed: 27304843
Am J Ophthalmol. 2021 Oct;230:123-133
pubmed: 33951446
Arch Ophthalmol. 2012 Jan;130(1):9-24
pubmed: 21911650
Invest Ophthalmol Vis Sci. 1979 Mar;18(3):263-72
pubmed: 422332
Am J Ophthalmol. 1947 Jun;30(6):705-20
pubmed: 20241735
Transl Vis Sci Technol. 2018 Nov 27;7(6):10
pubmed: 30510854
Doc Ophthalmol. 2009 Dec;119(3):217-24
pubmed: 19885692
N Engl J Med. 2015 May 14;372(20):1920-6
pubmed: 25936984
Br J Ophthalmol. 1985 May;69(5):326-39
pubmed: 3873253
Lancet. 2017 Aug 26;390(10097):849-860
pubmed: 28712537
Transl Vis Sci Technol. 2015 Apr 28;4(2):14
pubmed: 25938002
Transl Vis Sci Technol. 2020 Oct 08;9(11):9
pubmed: 33133772
N Engl J Med. 2008 May 22;358(21):2231-9
pubmed: 18441371
Ophthalmology. 2021 Oct;128(10):1460-1468
pubmed: 33798654